Major advances in scientific discovery and insights can result from the development and use of new techniques, as exemplified by the work of Solomon Snyder, who writes a prefatory article in this volume. The Editors have chosen “New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology” as the Theme for a number of articles in this volume. These include ones that review the development and use of new experimental tools and approaches (e.g., nanobodies and techniques to explore protein-protein interactions), new types of therapeutics (e.g., aptamers and antisense oligonucleotides), and systems pharmacology, which assembles (big) data derived from omics studies together with information regarding drugs and patients. The application of these new methods and therapeutic approaches has the potential to have a major impact on basic and clinical research in pharmacology and toxicology as well as on patient care.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Snyder SH. 1.  2017. A life of neurotransmitters. Annu. Rev. Pharmacol. Toxicol. 57:1–11 [Google Scholar]
  2. Manglik A, Kobilka BK, Steyaert J. 2.  2017. Nanobodies to study G protein–coupled receptor structure and function. Annu. Rev. Pharmacol. Toxicol 57:19–37 [Google Scholar]
  3. Corbi-Verge C, Garton M, Nim S, Kim PM. 3.  2017. Strategies to develop inhibitors of motif-mediated protein-protein interactions as drug leads. Annu. Rev. Pharmacol. Toxicol 57:39–60 [Google Scholar]
  4. Nimjee SM, White RR, Becker RC, Sullenger BA. 4.  2017. Aptamers as therapeutics. Annu. Rev. Pharmacol. Toxicol 57:61–79 [Google Scholar]
  5. Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. 5.  2017. Pharmacology of antisense drugs. Annu. Rev. Pharmacol. Toxicol 57:81–105 [Google Scholar]
  6. Bondeson DP, Crews CM. 6.  2017. Targeted protein degradation by small molecules. Annu. Rev. Pharmacol. Toxicol. 57:107–23 [Google Scholar]
  7. Riazifar M, Pone EJ, Lötvall J, Zhao W. 7.  2017. Stem cell extracellular vesicles: extended messages of regeneration. Annu. Rev. Pharmacol. Toxicol 57:125–54 [Google Scholar]
  8. Everts M, Cihlar T, Bostwick JR, Whitley RJ. 8. 2017 Accelerating drug development: antiviral therapies for emerging viruses as a model. Annu. Rev. Pharmacol. Toxicol 57:155–69 [Google Scholar]
  9. Hutson PH, Clark JA, Cross AJ. 9.  2017. CNS target identification and validation: avoiding the valley of death or naive optimism?. Annu. Rev. Pharmacol. Toxicol. 57:171–87 [Google Scholar]
  10. Khurana V, Tardiff DF, Chung CY, Lindquist S. 10.  2015. Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat. Rev. Neurol. 11:339–50 [Google Scholar]
  11. Haston KM, Finkbeiner S. 11.  2016. Clinical trials in a dish: the potential of pluripotent stem cells to develop therapies for neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 56:489–510 [Google Scholar]
  12. Yeaman MR, Hennessey JP Jr. 12.  2017. New approaches to improve anti-infective vaccine efficacy. Annu. Rev. Pharmacol. Toxicol 57:189–222 [Google Scholar]
  13. Burke AC, Dron JS, Hegele RA, Huff MW. 13.  2017. PCSK9: regulation and target for drug development for dyslipidemia. Annu. Rev. Pharmacol. Toxicol 57:223–44 [Google Scholar]
  14. Xie L, Draizen EJ, Bourne PE. 14.  2017. Harnessing big data for systems pharmacology. Annu. Rev. Pharmacol. Toxicol 57:245–62 [Google Scholar]
  15. Lavoie KL, Rash JA, Campbell TS. 15.  2017. Changing provider behavior in the context of chronic disease management: focus on clinical inertia. Annu. Rev. Pharmacol. Toxicol 57:263–83 [Google Scholar]
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error